Evidence map›Paper›PMID 36510237›Full record

ArticleBMC neurology2022

Antidepressants Trial in Parkinson's Disease (ADepT-PD): protocol for a randomised placebo-controlled trial on the effectiveness of escitalopram and nortriptyline on depressive symptoms in Parkinson's disease.

A Schrag, C Carroll, G Duncan, S Molloy, L Grover, R Hunter, R Brown, N Freemantle, J Whipps, M A Serfaty and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03652870 (A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03652870 phase3completednot on this map

A Randomised Placebo-Controlled Trial of Escitalopram and Nortriptyline With Standard Psychological Care for Depression in Parkinson's Disease

TypeinterventionalSponsorUniversity College, LondonRan2021 to 2023Enrolled52ConditionsDepression, Parkinson DiseaseArmsNortriptyline, Escitalopram, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Wild Mushrooms: A Hidden Treasure of Novel Bioactive Compounds.International journal of analytical chemistry · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

A SchragDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK. a.schrag@ucl.ac.uk.ORCID http://orcid.org/0000-0002-9872-6680
C CarrollFaculty of Medicine and Dentistry, University of Plymouth, Plymouth, UK.
G DuncanNHS Lothian, Edinburgh, UK.
S MolloyDepartment of Neurosciences, Imperial College Healthcare NHS Trust, London, UK.
L GroverDepartment of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, University College London, London, UK.
R HunterResearch Department of Primary Care and Population Health, University College London, London, UK.
R BrownDepartment of Psychology, Institute of Psychiatry, King's College London, London, UK.
N FreemantleComprehensive Clinical Trials Unit, University College London, London, UK.
J WhippsPPI Representative, Plymouth, UK.
M A SerfatyDivision of Psychiatry, UCL, London, UK.
G LewisDivision of Psychiatry, UCL, London, UK.
University College London · GBImperial College Healthcare NHS Trust · GBKing's College London · GBNational Hospital for Neurology and Neurosurgery · GBNHS Lothian · GBQueen Mary University of London · GBThe Priory Hospital · GBUniversity of Plymouth · GB

Funding

Cure Parkinson's Trust 3013387Health Technology Assessment Programme 16/145/01
6 · The paper itself

Abstract

backgroundDepressive symptoms are common in patients with Parkinson's disease and depression is a significant predictor of functional impairment, reduced quality of life and general well-being in Parkinson's disease. Despite the high prevalence of depression, evidence on the effectiveness and tolerability of antidepressants in this population is limited. The primary aim of this trial is to establish the clinical and cost effectiveness of escitalopram and nortriptyline for the treatment of depression in Parkinson's disease.

methodsThis is a multi-centre, double-blind, randomised placebo-controlled trial in 408 people with Parkinson's disease with subsyndromal depression, major depressive disorder or persistent depressive disorder and a Beck Depression Inventory-II (BDI-II) score of 14 or above. Participants will be randomised into one of three groups, receiving either escitalopram, nortriptyline or placebo for 12 months. Trial participation is face-to-face, hybrid or remote. The primary outcome measure is the BDI-II score following 8 weeks of treatment. Secondary outcomes will be collected at baseline, 8, 26 and 52 weeks and following withdrawal, including severity of anxiety and depression scores as well as Parkinson's disease motor severity, and ratings of non-motor symptoms, cognitive function, health-related quality of life, levodopa-equivalence dose, changes in medication, overall clinical effectiveness, capability, health and social care resource use, carer health-related quality of life, adverse effects and number of dropouts. DISCUSSION: This trial aims to determine the effectiveness of escitalopram and nortriptyline for reducing depressive symptoms in Parkinson's disease over 8 weeks, to provide information on the effect of these medications on anxiety and other non-motor symptoms in PD and on impact on patients and caregivers, and to examine their effect on change in motor severity.

trial registrationClinicalTrials.gov Identifier: NCT03652870 Date of registration - 29

Indexed as

Major Depressive DisorderParkinson DiseaseAntidepressive AgentsDouble-Blind MethodEscitalopramHumansMulticenter Studies as TopicNortriptylineQuality of LifeRandomized Controlled Trials as TopicTreatment OutcomeAntidepressive AgentsEscitalopramNortriptylineClinical effectivenessCost-effectivenessDepressive symptomsEscitalopramNortriptylineParkinson’s diseaseRandomised controlled trial

Identifiers

PMID36510237
PMCPMC9743717
OpenAlexW4311572521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.